Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS1001 Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma
CTR20180423Phase 2Completed
- Sponsor
- CStone Pharmaceuticals
- Start
- May 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of sugemalimab in classical Hodgkin lymphoma (cHL), sponsored by CStone Pharmaceuticals. Started May 2018; status: completed.
02
Drugs
sugemalimab
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on CTR20180423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180423.